PCSS-MOUD Exchange 4 – Session Roadmap, Session 1 – Explore
Topic: Review medications for opioid use disorders (MOUD), with a focus on buprenorphine treatment and its various formulations, and strategies for including harm reduction approaches into care. Discuss administrative, clinical, and financial considerations, and provide resources for both prescribers and non-prescribers.
PCSS-MOUD Exchange 4 – Session Roadmap, Session 2 – Prepare
Topic: Review patient screening considerations and discuss how OUD screening can be integrated into current clinic workflows. Discuss the training and certifications required for specific team members to implement MOUD. Highlight the critical role of Champions, and how to strategically select Champions to support MOUD implementation.
PCSS-MOUD Exchange 4 – Session Roadmap, Session 3 – Implement/Sustain
Topic: Review considerations for MOUD initiation and follow-up, including lab guidelines, and clinical management of patients with continued use (e.g., fentanyl, novel synthetic opioids), overdose risk, poly-substance use, and comorbid mental health conditions.
PCSS-MOUD Exchange 4 – Session Roadmap, Session 4 – Implement/Sustain
Topic: Consider approaches to sustain MOUD and ensure continued access to high-quality care for our most challenged patients, including those who are pregnant, youth/adolescents, those with acute or chronic pain, and those electing to taper their dose.
PCSS-MOUD Half and Half DEA Training
This training will be split between 2 dates, the first half on 8/4/2025 which will be held virtually and the second half which will be held in person on 8/11/2025 at the address included. To Register for the training please email: [email protected]
PCSS-MOUD Half and Half DEA Training
Training will be hosted virtually To Register, please email [email protected]
8 Hour Live DEA Training
This is a virtual training. To register, please click the “Register Here” button
PCSS-MOUD Half and Half DEA Training
This training is available virtually. To register, please email: [email protected].
Exchange Session 4 – Implement/Sustain
Consider approaches to sustain MOUD and ensure continued access to high-quality care for our most challenged patients, including those who are pregnant, youth/adolescents, those with acute or chronic pain, and those electing to taper their dose.
Exchange Session 3 – Implement/Sustain
Review considerations for MOUD initiation and follow-up, including lab guidelines, and clinical management of patients with continued use (e.g., fentanyl, novel synthetic opioids), overdose risk, poly-substance use, and comorbid mental health conditions.
